Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV 16/18 Bivalent Vaccine (Cecolin) in Healthy Females (18-25 Years)
NCT01356823Phase 2Completed
- Sponsor
- Xiamen University
- Start
- Mar 2011
- Primary completion
- Dec 2011
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human papillomavirus 16/18 bivalent vaccine in Cervical Cancer (CC) and cervical intraepithelial neoplasia (CIN) (4 arms), sponsored by Xiamen University. Primary endpoint: Seroconversion of anti-HPV 16 and anti-HPV 18 neutralizing antibody at 7 months. Started Mar 2011; status: completed.
02
Drugs
human papillomavirus 16/18 bivalent vaccine
03
Conditions
Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT01356823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01356823.